Skip to main content
Clinical Trials/CTRI/2015/01/005431
CTRI/2015/01/005431CompletedNot Applicable

Effect of intravenous dexmedetomidine administered as bolus or bolus plus infusion on subarachnoid block with hyperbaric bupivacaine

Manipal University1 site in 1 country75 target enrollmentStarted: March 6, 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
75
Locations
1
Primary Endpoint
onset of analgesia at T10.

Study Overview

Brief Summary

Dexmedetomidine is a highly selective alpha2 agonist and studies have shown that it prolongs motor, sensory blockade during spinal anaesthesia without undesirable side effects.

The aim of our study is to compare the effect of 1 ug/kg of intravenous dexmedetomidine, given either as a bolus(1 ug/kg) or bolus plus infusion(0.5 ug/kg) on subarachnoid anaesthesia with 12.5 mg of hyperbaric bupivacaine(2.5 ml

of 0.5 % bupivacaine).

observer 1 is the anaesthesia faculty who will prepare the drug dilutions and observer 2 is the postgraduate(principal investigator, blinded to the study ) who will administer subarachnoid anaesthesia, record the parameters and any complications during the study.

On the day of surgey the patients are allocated into one of  the 3 groups as per randomisation table.After shifting to the ot, monitors are attached, iv line secured and drugs will be administered as described previously.

All the parameters are then recorded till both sensory and motor recovery.

Study Design

Study Type
Interventional
Allocation
Computer generated randomization
Masking
Participant, Investigator and Outcome Assessor Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •patients undergoing elective infraumbilical or lower limb surgery in the supine position under spinal anaesthesia belonging to american society of anaesthesiologists physical status 1 or 2.

Exclusion Criteria

  • •Patients who do not consent for subarachnoid anaesthesia Patients with coagulopathy, hypovolaemia, BMI > 35 kg/m2, spinal abnormalities Chronic use of sedatives or antidepressants History of regular alcohol consumption Local infection over lumbar spine.

Outcomes

Primary Outcomes

onset of analgesia at T10.

Time Frame: onset of analgesia at T10.sensory level then checked every 2 mins till | highest level of analgesia achieved then every 5 mins till end of 1 hr and every 15 mins till | 2 segment regression, recovery. | time of recovery at S2-3. | motor blockade assessed using modified bromage score.onset time is when bromage score of 3 is obtained and motor recovery when modified score is 0. | sedation score.sedation score recorded using ramsay sedation score every 15 mins throughout first 3 hrs.

2 segment regression.

Time Frame: onset of analgesia at T10.sensory level then checked every 2 mins till | highest level of analgesia achieved then every 5 mins till end of 1 hr and every 15 mins till | 2 segment regression, recovery. | time of recovery at S2-3. | motor blockade assessed using modified bromage score.onset time is when bromage score of 3 is obtained and motor recovery when modified score is 0. | sedation score.sedation score recorded using ramsay sedation score every 15 mins throughout first 3 hrs.

highest level of analgesia.

Time Frame: onset of analgesia at T10.sensory level then checked every 2 mins till | highest level of analgesia achieved then every 5 mins till end of 1 hr and every 15 mins till | 2 segment regression, recovery. | time of recovery at S2-3. | motor blockade assessed using modified bromage score.onset time is when bromage score of 3 is obtained and motor recovery when modified score is 0. | sedation score.sedation score recorded using ramsay sedation score every 15 mins throughout first 3 hrs.

recovery at S2-3.

Time Frame: onset of analgesia at T10.sensory level then checked every 2 mins till | highest level of analgesia achieved then every 5 mins till end of 1 hr and every 15 mins till | 2 segment regression, recovery. | time of recovery at S2-3. | motor blockade assessed using modified bromage score.onset time is when bromage score of 3 is obtained and motor recovery when modified score is 0. | sedation score.sedation score recorded using ramsay sedation score every 15 mins throughout first 3 hrs.

onset of motor block and recovery .

Time Frame: onset of analgesia at T10.sensory level then checked every 2 mins till | highest level of analgesia achieved then every 5 mins till end of 1 hr and every 15 mins till | 2 segment regression, recovery. | time of recovery at S2-3. | motor blockade assessed using modified bromage score.onset time is when bromage score of 3 is obtained and motor recovery when modified score is 0. | sedation score.sedation score recorded using ramsay sedation score every 15 mins throughout first 3 hrs.

sedation score.

Time Frame: onset of analgesia at T10.sensory level then checked every 2 mins till | highest level of analgesia achieved then every 5 mins till end of 1 hr and every 15 mins till | 2 segment regression, recovery. | time of recovery at S2-3. | motor blockade assessed using modified bromage score.onset time is when bromage score of 3 is obtained and motor recovery when modified score is 0. | sedation score.sedation score recorded using ramsay sedation score every 15 mins throughout first 3 hrs.

Secondary Outcomes

  • haemodynamic parameters-blood pressure, heart rate, saturation. other side effects like nausea, vomiting or pruritus(BP and heart rate every 2.5 mins for first 15 mins.then 5 mins for first hour and then every 15 mins till complete recovery.)

Investigators

Sponsor Class
Private medical college

Study Sites (1)

Loading locations...

Similar Trials